Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2,3-Dihydroxybenzoic acid is a natural phenolic compound and a dihydroxybenzoic acid derivative with hydroxy groups at positions 2 and 3 of the benzoic ring. It occurs naturally in plants such as Phyllanthus acidus and Salvinia molesta and is also produced by certain bacteria including Escherichia coli. In humans, it can be formed as a metabolite of aspirin. The compound acts as an **iron chelator**—binding to iron ions—and has been studied for its potential use in treating iron overload conditions such as beta-thalassemia major. Its mechanism involves chelation of free iron ions to promote their excretion from the body[5][8]. Additionally, it serves as a biological marker for hydroxyl radical formation due to its generation during oxidative attack on salicylic acids[4]. It also exhibits antimicrobial properties[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2,3-dihydroxybenzoic acid.